← Eichor
Condition: Concurrent Chemoradiotherapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Concurrent Chemoradiotherapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
Phase 2 · 12 location(s) · Sun Yat-sen University · NCT06455410Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous C
Phase 2 · 1 location(s) · Tongji Hospital · NCT07699185Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05511623Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06452602Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invas
Phase 3 · 11 location(s) · Astellas Pharma Global Development, Inc. · NCT07566156Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06667622CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Phase 3 · 1 location(s) · Fudan University · NCT06964568A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck S
Phase 1 · 17 location(s) · Johnson & Johnson Enterprise Innovation Inc. · NCT07219212Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
Phase 3 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT07150663A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nas
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07392320Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical C
Phase N/A · 1 location(s) · Guizhou Provincial People's Hospital · NCT05950087A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07103395IA Carboplatin + Radiotherapy in Relapsing GBM
Phase 1/Phase 2 · 1 location(s) · Université de Sherbrooke · NCT03672721GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06851247Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy fo
Phase 2 · 1 location(s) · The First Affiliated Hospital of Henan University of Science · NCT07622797Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07609121Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Phase 3 · 205 location(s) · AstraZeneca · NCT06079671Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unres
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07086469An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly
Phase N/A · 1 location(s) · Three Gorges Hospital of Chongqing University · NCT07080437Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
Phase 2 · 1 location(s) · Chongqing University Cancer Hospital · NCT05687851Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
Phase 3 · 3 location(s) · Sun Yat-sen University · NCT07052669Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcin
Phase 3 · 2 location(s) · Wei Jiang · NCT05527470Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Ca
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07636824A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esoph
NA · 2 location(s) · The Central Hospital of Lishui City · NCT06792786Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06341595Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07232654Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Phase 2/Phase 3 · 12 location(s) · Tongji Hospital · NCT06288373The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cer
NA · 1 location(s) · Chongqing University Cancer Hospital · NCT05749887Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Ca
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT04980716
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.